Endoxan 1G



Indications and Reactions:

Role Indications Reactions
Primary
Hodgkin's Disease 18.2%
B-cell Lymphoma 14.1%
Product Used For Unknown Indication 11.2%
Non-hodgkin's Lymphoma 10.2%
Chronic Lymphocytic Leukaemia 10.1%
Breast Cancer 10.1%
Drug Use For Unknown Indication 5.0%
Nodular (Follicular) Lymphoma 3.4%
Prophylaxis 3.2%
Diffuse Large B-cell Lymphoma 2.8%
Premedication 1.7%
Human Immunodeficiency Virus Type I Infection With Secondary Cancers 1.5%
Lymphoma 1.4%
Malignant Breast Neoplasm 1.3%
Hypertension 1.1%
Acute Leukaemia 1.0%
Her-2 Positive Breast Cancer 1.0%
Peripheral T-cell Lymphoma Unspecified 1.0%
Constipation 0.9%
Foetal Exposure Timing Unspecified 0.8%
Neutropenic Infection 19.2%
Infection 17.1%
Hepatitis B 9.9%
No Adverse Event 6.5%
Pneumonia 6.2%
Myelodysplastic Syndrome 5.1%
General Physical Health Deterioration 4.1%
Sepsis 3.8%
Vomiting 3.8%
Death 3.1%
Febrile Neutropenia 2.7%
Neutropenia 2.7%
Pulmonary Embolism 2.4%
Pyrexia 2.4%
Thrombocytopenia 2.4%
Syncope 2.1%
Neutropenic Sepsis 1.7%
Respiratory Failure 1.7%
Upper Respiratory Tract Infection 1.7%
Pancytopenia 1.4%
Secondary
Product Used For Unknown Indication 28.4%
B-cell Lymphoma 23.2%
Breast Cancer 9.0%
Drug Use For Unknown Indication 6.5%
Prophylaxis 4.0%
Diffuse Large B-cell Lymphoma 3.7%
Her-2 Positive Breast Cancer 3.1%
Premedication 2.9%
Non-hodgkin's Lymphoma 2.8%
Constipation 2.3%
Malignant Breast Neoplasm 1.9%
Chemotherapy 1.7%
Chronic Lymphocytic Leukaemia 1.4%
Hodgkin's Disease 1.4%
Hypertension 1.4%
Infection Prophylaxis 1.4%
Nausea 1.4%
Hodgkin's Lymphoma 1.2%
Nodular (Follicular) Lymphoma 1.2%
Pain 1.1%
Neutropenia 18.0%
Pneumonia 11.5%
Vomiting 9.8%
General Physical Health Deterioration 6.6%
Death 4.9%
Febrile Neutropenia 4.9%
Herpes Zoster 4.9%
Pyrexia 4.9%
Exposure During Pregnancy 3.3%
Myelodysplastic Syndrome 3.3%
Neoplasm 3.3%
Premature Delivery 3.3%
Pulmonary Embolism 3.3%
Purulence 3.3%
Sinusitis 3.3%
Tachycardia 3.3%
Upper Respiratory Tract Infection 3.3%
Atrial Flutter 1.6%
Bronchitis 1.6%
Circulatory Collapse 1.6%